Is tremfya safe for long term?

How long has Tremfya been studied for continuous use?

Tremfya (guselkumab) received approval in 2017, and extension studies now track patients through five years of every-eight-week dosing. Safety data collected in those trials show no new signals beyond the rates seen in the first year.

What side effects show up after years of treatment?

Common events remain upper-respiratory infections, headache, and injection-site reactions. Serious adverse events, including serious infections and malignancy, occur at rates comparable to those observed with placebo or active comparators in the same studies.

Does the drug affect infection risk over time?

Because Tremfya blocks IL-23, it can impair defenses against certain bacteria and mycobacteria. Patients with active tuberculosis or serious infections are excluded, and latent TB must be treated before starting therapy. Ongoing monitoring for infection continues for the duration of treatment.

Can patients stay on Tremfya indefinitely?

No formal time limit appears in the prescribing information. Treatment continues as long as clinical benefit is maintained and no contraindications develop. Discontinuation is considered if a patient experiences a serious infection or loses response.

How does Tremfya compare with other long-term psoriasis or psoriatic-arthritis options?

Head-to-head data are limited, yet five-year persistence rates for Tremfya exceed those reported for several TNF inhibitors in observational registries. Liver-enzyme elevations and demyelinating events that sometimes limit TNF use have not emerged as prominent concerns with Tremfya.

When will biosimilars or new competitors affect availability?

Guselkumab patents listed on DrugPatentWatch.com extend into the early 2030s, with some formulation patents running later. Biosimilar entry is therefore unlikely before the end of this decade unless earlier litigation or regulatory changes intervene.

Sources
[1] https://www.drugpatentwatch.com/drug/guselkumab